Camel milk vs. cow milk: which helps athletes recover faster?
NCT ID NCT07491705
First seen Jun 27, 2026 ยท Last updated Jun 27, 2026
Summary
This study looked at whether drinking camel milk after intense exercise helps healthy men recover better than cow milk or water. Twelve recreationally active men did cycling tests and drank one of the three beverages. Researchers measured how long they could cycle, heart rate, muscle soreness, and inflammation markers. The goal was to see if camel milk improves recovery and performance, but the study is small and only in men, so results are preliminary.
What this could mean
Our plain-language read of the trial. This is informational only โ not medical advice or a prediction.
- Active substance
- camel milk
- What this could lead to
- If camel milk proves beneficial, it could offer a natural recovery drink for athletes.
- What could go wrong
- This is a very small, early-stage study in healthy men only. Results may not apply to women, older people, or those with health conditions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
United Arab Emirates University Building E3 Room 0015
Al Ain City, Abu Dhabi Emirate, 15551, United Arab Emirates
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test